Novel antiarrhythmic compounds with combined class IB and class III mode of action

P. Mátyus, Ildikó Varga, Tivadar Rettegi, Antal Simay, Péter Kovács, László Károlyházy, Ákos Kocsis, Szilvia Vajda, A. Varró, István Pénzes, J. Papp

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I/B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N- (phenylalkyl)-N-(phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate. All rights reserved -

Original languageEnglish
Pages (from-to)113-124
Number of pages12
JournalFrontiers in Medicinal Chemistry
Volume3
Issue number1
Publication statusPublished - 2006

Fingerprint

Amiodarone
Anti-Arrhythmia Agents
Cardiac Arrhythmias
Bearings (structural)
Drug therapy
Cardiovascular Agents
Amines
Screening
Clinical Trials
Pharmacology
Drug Therapy
Molecules
Mortality
Research
GYKI 16638

Keywords

  • Class I/B
  • Class III antiarrhythmics
  • Dual mode of action
  • GYKI 16638
  • N-(phenylalkyl)-N-(phenoxyalkyl)amines

ASJC Scopus subject areas

  • Organic Chemistry
  • Molecular Medicine
  • Drug Discovery
  • Pharmaceutical Science
  • Biochemistry

Cite this

Mátyus, P., Varga, I., Rettegi, T., Simay, A., Kovács, P., Károlyházy, L., ... Papp, J. (2006). Novel antiarrhythmic compounds with combined class IB and class III mode of action. Frontiers in Medicinal Chemistry, 3(1), 113-124.

Novel antiarrhythmic compounds with combined class IB and class III mode of action. / Mátyus, P.; Varga, Ildikó; Rettegi, Tivadar; Simay, Antal; Kovács, Péter; Károlyházy, László; Kocsis, Ákos; Vajda, Szilvia; Varró, A.; Pénzes, István; Papp, J.

In: Frontiers in Medicinal Chemistry, Vol. 3, No. 1, 2006, p. 113-124.

Research output: Contribution to journalArticle

Mátyus, P, Varga, I, Rettegi, T, Simay, A, Kovács, P, Károlyházy, L, Kocsis, Á, Vajda, S, Varró, A, Pénzes, I & Papp, J 2006, 'Novel antiarrhythmic compounds with combined class IB and class III mode of action', Frontiers in Medicinal Chemistry, vol. 3, no. 1, pp. 113-124.
Mátyus P, Varga I, Rettegi T, Simay A, Kovács P, Károlyházy L et al. Novel antiarrhythmic compounds with combined class IB and class III mode of action. Frontiers in Medicinal Chemistry. 2006;3(1):113-124.
Mátyus, P. ; Varga, Ildikó ; Rettegi, Tivadar ; Simay, Antal ; Kovács, Péter ; Károlyházy, László ; Kocsis, Ákos ; Vajda, Szilvia ; Varró, A. ; Pénzes, István ; Papp, J. / Novel antiarrhythmic compounds with combined class IB and class III mode of action. In: Frontiers in Medicinal Chemistry. 2006 ; Vol. 3, No. 1. pp. 113-124.
@article{b8f798e927de4d2c9c8516212a9fdaec,
title = "Novel antiarrhythmic compounds with combined class IB and class III mode of action",
abstract = "Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I/B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N- (phenylalkyl)-N-(phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate. All rights reserved -",
keywords = "Class I/B, Class III antiarrhythmics, Dual mode of action, GYKI 16638, N-(phenylalkyl)-N-(phenoxyalkyl)amines",
author = "P. M{\'a}tyus and Ildik{\'o} Varga and Tivadar Rettegi and Antal Simay and P{\'e}ter Kov{\'a}cs and L{\'a}szl{\'o} K{\'a}rolyh{\'a}zy and {\'A}kos Kocsis and Szilvia Vajda and A. Varr{\'o} and Istv{\'a}n P{\'e}nzes and J. Papp",
year = "2006",
language = "English",
volume = "3",
pages = "113--124",
journal = "Frontiers in Drug Design and Discovery",
issn = "1574-2042",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Novel antiarrhythmic compounds with combined class IB and class III mode of action

AU - Mátyus, P.

AU - Varga, Ildikó

AU - Rettegi, Tivadar

AU - Simay, Antal

AU - Kovács, Péter

AU - Károlyházy, László

AU - Kocsis, Ákos

AU - Vajda, Szilvia

AU - Varró, A.

AU - Pénzes, István

AU - Papp, J.

PY - 2006

Y1 - 2006

N2 - Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I/B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N- (phenylalkyl)-N-(phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate. All rights reserved -

AB - Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I/B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N- (phenylalkyl)-N-(phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate. All rights reserved -

KW - Class I/B

KW - Class III antiarrhythmics

KW - Dual mode of action

KW - GYKI 16638

KW - N-(phenylalkyl)-N-(phenoxyalkyl)amines

UR - http://www.scopus.com/inward/record.url?scp=40249117411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40249117411&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:40249117411

VL - 3

SP - 113

EP - 124

JO - Frontiers in Drug Design and Discovery

JF - Frontiers in Drug Design and Discovery

SN - 1574-2042

IS - 1

ER -